1. Omega-3s vs Pure EPA in Clinical Practice

2. Rationale for the Use of Fish Oil

3. Primary and Secondary CVD Prevention Trials Evaluating Treatment of TGs

4. Rationale for the Use of Highly Purified EPA

5. REDUCE-IT Study Design

6. REDUCE-IT Primary and Secondary Endpoint Results

7. REDUCE-IT Prespecified Hierarchical Testing

8. REDUCE-IT CV Benefit of EPA Independent of LDL-C Levels

9. Ischemic Event Reduction With Icosapent Ethyl

10. Ischemic Event Reduction With Icosapent Ethyl Statistical Handling

11. REDUCE-IT Analysis Reduction of First and Subsequent Events

12. First and Total Events Over the Years

13. Primary Composite Endpoint Total Endpoint Events by Baseline TG Tertiles

14. REDUCE-IT Change in Biomarkers After 1 Year

15. Risk Differences With Icosapent Ethyl

16. Safety Results

17. REDUCE-IT Serious Bleeding

18. Medications Taken at Baseline

19. Membrane Stabilization

20. Effects of EPA on Plaque Progression

21. Prescription-Only Omega-3s vs Dietary Supplement Omega-3s

22. 2018 Cholesterol Guidelines Secondary Prevention in Patients With Clinical ASCVD

23. Collaborative Care

24. Conclusion

25. Abbreviations

26. Abbreviations (cont)

27. Abbreviations (cont)